Comparison of Local Subcutaneous Infiltration with Ropivacaine Alone and Two Different Doses of Dexmedetomidine Plus Ropivacaine for Postoperative Pain after Cesarean Section Under Spinal Anesthesia.
{"title":"Comparison of Local Subcutaneous Infiltration with Ropivacaine Alone and Two Different Doses of Dexmedetomidine Plus Ropivacaine for Postoperative Pain after Cesarean Section Under Spinal Anesthesia.","authors":"Atefeh Ghosouri, Alireza Hoghooghy, Azim Honarmand, Arefeh Kabirzadeh","doi":"10.4103/abr.abr_253_24","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>In a cesarean section (CS), good postoperative pain management is of great importance. We assessed the effect of adding dexmedetomidine to ropivacaine 0.5% in CS patients with spinal anesthesia to assess its ability to enhance pain management.</p><p><strong>Materials and methods: </strong>This was a randomized controlled trial in Shahid Beheshti Hospital between 2022 and 2023 with the goal of assessing ropivacaine efficacy with and without dexmedetomidine on pain control after a CS. Spinal anesthesia was administered for all patients by using bupivacaine 0.5%. Before wound closure, patients were treated with analgesics. Group A received dexmedetomidine 1 µg/kg infiltrated subcutaneously, followed by ropivacaine 0.5% 3 mg/kg diluted with normal saline to 40 cc. Group B received dexmedetomidine 2 µg/kg, followed by ropivacaine 0.5% 3 mg/kg. The control group received ropivacaine 0.5% 3 mg/kg. A <i>P</i> value of < 0.05was regarded as significant.</p><p><strong>Results: </strong>The study groups exhibited significantly lower visual analog scale (VAS) pain scores. Specifically, group A showed significantly lower VAS scores than the controls, and group B also showed significantly lower VAS scores than group A. The VAS score after 24 hours of CS was, on average, 2.13 (SD = 0.16, 95% CI = [1.74, 2.52]) lower in group B compared to the control group and 1.1 (SD = 0.16, 95% CI = [0.71, 1.49]) lower than in group A (<i>P</i> < 0.05).</p><p><strong>Conclusions: </strong>Subcutaneous infiltration of dexmedetomidine with ropivacaine improves postoperative pain management more effectively than using ropivacaine alone. It is noteworthy that dexmedetomidine 2 µg/kg can improve pain after a CS more effectively than 1 µg/kg.</p>","PeriodicalId":94292,"journal":{"name":"Advanced biomedical research","volume":"14 ","pages":"52"},"PeriodicalIF":0.7000,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12165305/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced biomedical research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/abr.abr_253_24","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: In a cesarean section (CS), good postoperative pain management is of great importance. We assessed the effect of adding dexmedetomidine to ropivacaine 0.5% in CS patients with spinal anesthesia to assess its ability to enhance pain management.
Materials and methods: This was a randomized controlled trial in Shahid Beheshti Hospital between 2022 and 2023 with the goal of assessing ropivacaine efficacy with and without dexmedetomidine on pain control after a CS. Spinal anesthesia was administered for all patients by using bupivacaine 0.5%. Before wound closure, patients were treated with analgesics. Group A received dexmedetomidine 1 µg/kg infiltrated subcutaneously, followed by ropivacaine 0.5% 3 mg/kg diluted with normal saline to 40 cc. Group B received dexmedetomidine 2 µg/kg, followed by ropivacaine 0.5% 3 mg/kg. The control group received ropivacaine 0.5% 3 mg/kg. A P value of < 0.05was regarded as significant.
Results: The study groups exhibited significantly lower visual analog scale (VAS) pain scores. Specifically, group A showed significantly lower VAS scores than the controls, and group B also showed significantly lower VAS scores than group A. The VAS score after 24 hours of CS was, on average, 2.13 (SD = 0.16, 95% CI = [1.74, 2.52]) lower in group B compared to the control group and 1.1 (SD = 0.16, 95% CI = [0.71, 1.49]) lower than in group A (P < 0.05).
Conclusions: Subcutaneous infiltration of dexmedetomidine with ropivacaine improves postoperative pain management more effectively than using ropivacaine alone. It is noteworthy that dexmedetomidine 2 µg/kg can improve pain after a CS more effectively than 1 µg/kg.